InspireMD's CGuard EPS Treats Patients in Hong Kong

Biotech Investing

InspireMD announced the positive treatment of two patients in Hong Kong using CGuard EPS.

InspireMD (NYSEMKT:NSPR) announced the positive treatment of the first two patients in Hong Kong using CGuard EPS.
As quoted in the press release:

The two cases were conducted on patients with carotid artery stenosis at St. Teresa Hospital by Dr. PW Cheng and Dr. YW Chow, a leading neurointerventional radiologist and leading cardiologist, respectively.
These first cases in Hong Kong follow the previously announced distribution agreement for CGuard™ EPS with a distribution partner in Hong Kong that was announced two months ago. These are the first cases performed in the Asia Pacific region and represent a further milestone for InspireMD’s global expansion strategy.
Dr. PW Cheng and Dr. YW Chow commented, “These procedures went seamlessly and we are very pleased with the way CGuard performed. We are very excited to have access to this innovative technology as it provides vastly superior safety to carotid artery stenting (CAS) patients compared to conventional stents. We envision this procedure becoming the standard of care for carotid stenting procedures.”

Click here to read the full press release.

Source: www.marketwired.com

The Conversation (0)
×